Nuvectis Pharma
NVCTPhase 1Nuvectis Pharma is a publicly traded, clinical-stage biotech focused on targeted cancer therapies. Its lead assets are NXP900, a unique Type 1.5 SRC/YES1 inhibitor advancing into Phase 1b trials, and NXP800, a GCN2 activator being explored in ARID1a-mutated ovarian cancer and cholangiocarcinoma. The company is led by a seasoned management team with prior successful drug development and commercialization experience.
NVCT · Stock Price
Historical price data
AI Company Overview
Nuvectis Pharma is a publicly traded, clinical-stage biotech focused on targeted cancer therapies. Its lead assets are NXP900, a unique Type 1.5 SRC/YES1 inhibitor advancing into Phase 1b trials, and NXP800, a GCN2 activator being explored in ARID1a-mutated ovarian cancer and cholangiocarcinoma. The company is led by a seasoned management team with prior successful drug development and commercialization experience.
Technology Platform
Focuses on developing targeted small molecules with novel mechanisms of action, such as Type 1.5 kinase inhibition and kinase activation, for precision oncology applications.
Pipeline Snapshot
33 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| NXP900 + Osimertinib | EGFR Mutation Positive Non-small Cell Lung Cancer | Phase 1 |
| NXP900 | Advanced Solid Tumor | Phase 1 |
| NXP800 | Advanced Solid Tumor | Phase 1 |
Funding History
2Total raised: $25M
Opportunities
Risk Factors
Competitive Landscape
NXP900 competes in the SRC/YES1 kinase inhibitor space, which has seen historical challenges. Its differentiation lies in its novel Type 1.5 mechanism. NXP800, as a GCN2 activator, faces less direct competition but must prove efficacy in difficult-to-treat cancers. The company's precision medicine strategy is its primary competitive tactic.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile